Pacira BioSciences' Current Deferred Revenue fell 82.86% to $102,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $102,000, marking a year-over-year decrease of 82.86%. This contributed to the annual value of $102,000 for FY2017, which is 82.86% down from last year.
According to the latest figures from Q4 2017, Pacira BioSciences' Current Deferred Revenue is $102,000, which was down 80.38% from $520,000 recorded in Q1 2017.
Pacira BioSciences' Current Deferred Revenue's 5-year high stood at $1.4 million during Q2 2014, with a 5-year trough of $102,000 in Q4 2017.
In the last 3 years, Pacira BioSciences' Current Deferred Revenue had a median value of $1.2 million in 2016 and averaged $1.0 million.
In the last 5 years, Pacira BioSciences' Current Deferred Revenue crashed by 86.56% in 2013 and then spiked by 46.71% in 2014.
Over the past 5 years, Pacira BioSciences' Current Deferred Revenue (Quarterly) stood at $1.0 million in 2013, then surged by 41.47% to $1.4 million in 2014, then remained steady at $1.4 million in 2015, then slumped by 58.27% to $595,000 in 2016, then tumbled by 82.86% to $102,000 in 2017.
Its last three reported values are $102,000 in Q4 2017, $520,000 for Q1 2017, and $595,000 during Q4 2016.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value